CY1119981T1 - Λιπιδιωμενα παραγωγα ιμιδαζοκινολινης - Google Patents

Λιπιδιωμενα παραγωγα ιμιδαζοκινολινης

Info

Publication number
CY1119981T1
CY1119981T1 CY20181100086T CY181100086T CY1119981T1 CY 1119981 T1 CY1119981 T1 CY 1119981T1 CY 20181100086 T CY20181100086 T CY 20181100086T CY 181100086 T CY181100086 T CY 181100086T CY 1119981 T1 CY1119981 T1 CY 1119981T1
Authority
CY
Cyprus
Prior art keywords
imidazokinoline
fat products
compounds
cytokine stimuli
phospho
Prior art date
Application number
CY20181100086T
Other languages
English (en)
Inventor
David Johnson
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of CY1119981T1 publication Critical patent/CY1119981T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Οι ενώσεις της υπό συζήτηση εφεύρεσης είναι ανοσοενισχυτικά μόρια που περιλαμβάνουν μόριο ιμιδαζοκινολίνης ομοιοπολικώς συνδεδεμένο προς φωσφο- ή φωσφονολιπιδίου ομάδα. Οι ενώσεις της εφεύρεσης έχει δειχθεί ότι είναι διεγέρτες ιντερφερόνης-a, IL-12 και άλλων ανοσοδιεγερτικών κυτταροκινών και διαθέτουν βελτιωμένο προφίλ δραστικότητας εν συγκρίσει προς γνωστούς διεγέρτες κυτταροκίνης όταν χρησιμοποιούνται ως ανοσοενισχυτικά για εμβόλιο αντιγόνων.
CY20181100086T 2008-10-24 2018-01-23 Λιπιδιωμενα παραγωγα ιμιδαζοκινολινης CY1119981T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10821008P 2008-10-24 2008-10-24
US22422609P 2009-07-09 2009-07-09
US22993309P 2009-07-30 2009-07-30
PCT/US2009/061867 WO2010048520A1 (en) 2008-10-24 2009-10-23 Lipidated imidazoquinoline derivatives

Publications (1)

Publication Number Publication Date
CY1119981T1 true CY1119981T1 (el) 2018-12-12

Family

ID=42119702

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100086T CY1119981T1 (el) 2008-10-24 2018-01-23 Λιπιδιωμενα παραγωγα ιμιδαζοκινολινης

Country Status (23)

Country Link
US (2) US8624029B2 (el)
EP (1) EP2341933B1 (el)
JP (1) JP5695569B2 (el)
KR (1) KR20110077004A (el)
CN (1) CN102264394B (el)
AU (1) AU2009308278B2 (el)
BR (1) BRPI0919937A2 (el)
CA (1) CA2741291A1 (el)
CY (1) CY1119981T1 (el)
DK (1) DK2341933T3 (el)
ES (1) ES2656813T3 (el)
HR (1) HRP20180063T1 (el)
HU (1) HUE036531T2 (el)
IL (1) IL212417A (el)
LT (1) LT2341933T (el)
MX (1) MX2011004249A (el)
NO (1) NO2341933T3 (el)
PL (1) PL2341933T3 (el)
PT (1) PT2341933T (el)
SI (1) SI2341933T1 (el)
TR (1) TR201802083T4 (el)
WO (1) WO2010048520A1 (el)
ZA (1) ZA201103590B (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
WO2011049825A1 (en) 2009-10-22 2011-04-28 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
US20120177681A1 (en) * 2010-09-01 2012-07-12 Manmohan Singh Formulation of immunopotentiators
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
EP2674170B1 (en) * 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
US20140242112A1 (en) * 2012-11-30 2014-08-28 Glaxosmithkline Biologicals S.A. Novel vaccine
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US9295732B2 (en) 2013-02-22 2016-03-29 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US10471139B2 (en) * 2013-08-15 2019-11-12 The University Of Kansas Toll-like receptor agonists
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
CN106715431A (zh) 2014-09-16 2017-05-24 吉利德科学公司 Toll样受体调节剂的固体形式
JP2017533925A (ja) 2014-11-13 2017-11-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アレルギー性疾患又は他の炎症状態の治療に有用なアデニン誘導体
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
WO2017056494A1 (en) 2015-09-29 2017-04-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
RU2759917C2 (ru) 2015-10-07 2021-11-18 Сумитомо Дайниппон Фарма Ко., Лтд. Пиримидиновое соединение
CN108368138A (zh) * 2015-12-14 2018-08-03 葛兰素史密丝克莱恩生物有限公司 咪唑并喹啉类和氧代腺嘌呤类的磷酸脂化
JP2019500360A (ja) * 2015-12-14 2019-01-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｔｌｒ７及びｔｌｒ８アゴニストとしてのｐｅｇ化されたイミダゾキノリン
US9966457B2 (en) * 2016-03-18 2018-05-08 Globalfoundries Inc. Transistor structure with varied gate cross-sectional area
US11274115B2 (en) 2016-09-07 2022-03-15 Glaxosmithkline Biological Sa Imidazoquinoline derivatives and their use in therapy
CA3057813A1 (en) 2017-03-29 2018-10-04 Sumitomo Dainippon Pharma Co., Ltd. Vaccine adjuvant formulation
WO2019124500A1 (ja) 2017-12-21 2019-06-27 大日本住友製薬株式会社 Ｔｌｒ７アゴニストを含む併用薬
WO2020022272A1 (ja) 2018-07-23 2020-01-30 公益財団法人ヒューマンサイエンス振興財団 インフルエンザワクチンを含む組成物
CA3138461A1 (en) 2019-05-23 2020-11-26 Helene Bazin-Lee Vaccine adjuvants based on tlr receptor ligands
CN112778372A (zh) * 2019-11-11 2021-05-11 苏州泽璟生物制药股份有限公司 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用
US20230373997A1 (en) * 2020-10-08 2023-11-23 Icahn School Of Medicine At Mount Sinai Imdq-peg-chol adjuvant and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ285420B6 (cs) * 1990-04-24 1999-08-11 Ústav Organické Chemie A Biochemie Avčr N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití
US5466467A (en) * 1994-03-30 1995-11-14 The United States Of America As Represented By The Secretary Of The Navy Liposomes containing polymerized lipids for non-covalent immobilization of proteins and enzymes
JP2005519990A (ja) * 2001-10-12 2005-07-07 ユニバーシティ オブ アイオワ リサーチ ファウンデーション イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物
CN1671412B (zh) 2002-08-15 2010-05-26 3M创新有限公司 免疫刺激组合物及刺激免疫反应的方法
EP1617872A4 (en) 2003-04-10 2011-09-07 3M Innovative Properties Co METHODS AND COMPOSITIONS FOR ENHANCING AN IMMUNE RESPONSE
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
BRPI0414856A (pt) * 2003-10-03 2006-11-21 3M Innovative Properties Co imidazoquinolinas alcóxi-substituìdas
EP1550458A1 (en) * 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
US20060051374A1 (en) * 2004-04-28 2006-03-09 3M Innovative Properties Company Compositions and methods for mucosal vaccination
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
RU2415857C2 (ru) * 2004-09-14 2011-04-10 Новартис Вэксинс Энд Диагностикс Инк. Имидазохинолиновые соединения
JP2009520730A (ja) * 2005-12-23 2009-05-28 ヤド・テヒノロギース・ゲーエムベーハー アレルギー性疾患を治療および予防するための手段および方法

Also Published As

Publication number Publication date
NO2341933T3 (el) 2018-04-21
PL2341933T3 (pl) 2018-04-30
BRPI0919937A2 (pt) 2016-02-16
EP2341933A4 (en) 2012-03-14
ES2656813T3 (es) 2018-02-28
JP2012506865A (ja) 2012-03-22
EP2341933A1 (en) 2011-07-13
MX2011004249A (es) 2011-07-20
JP5695569B2 (ja) 2015-04-08
DK2341933T3 (da) 2018-01-29
TR201802083T4 (tr) 2018-03-21
KR20110077004A (ko) 2011-07-06
AU2009308278B2 (en) 2014-11-27
ZA201103590B (en) 2012-10-31
IL212417A (en) 2017-01-31
CN102264394A (zh) 2011-11-30
US8946421B2 (en) 2015-02-03
SI2341933T1 (en) 2018-03-30
US8624029B2 (en) 2014-01-07
CA2741291A1 (en) 2010-04-29
PT2341933T (pt) 2018-02-13
CN102264394B (zh) 2014-01-01
US20140323731A1 (en) 2014-10-30
LT2341933T (lt) 2018-04-10
EP2341933B1 (en) 2017-11-22
WO2010048520A1 (en) 2010-04-29
IL212417A0 (en) 2011-06-30
HUE036531T2 (hu) 2018-07-30
HRP20180063T1 (hr) 2018-02-23
US20110282061A1 (en) 2011-11-17
AU2009308278A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
CY1119981T1 (el) Λιπιδιωμενα παραγωγα ιμιδαζοκινολινης
CY1123609T1 (el) Βελτιστοποιηση αντισωματων που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (lag-3), και χρησεις εξ΄ αυτων
CY1121789T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
CY1117689T1 (el) Συνθεσεις που περιλαμβανουν πνευμονιοκοκκικα αντιγονα
CY1121989T1 (el) Φαρμακοτεχνικες μορφες αντισωματων
CY1118815T1 (el) Συνθεσεις, φαρμακοτεχνικες μορφες και μεθοδοι λιπιδιωμενων ενωσεων τροποποιητων ανοσολογικης απαντησης
DK2280721T3 (da) Indoleamin-2, 3-dioxygenasebaseret immunterapi
CY1122235T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και του γαστρικου καρκινου
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1120319T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου που περιλαμβανουν haemophilus influenzae πρωτεϊνη ε και πιλινη α
CY1118874T1 (el) Ανθρωποποιημενα αντισωματα εναντια στη liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1115502T1 (el) Παραγοντες διεγερσης αποπτωσης για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
CY1118760T1 (el) Τροποποιημενα αντισωματα εναντι il-23
CY1119066T1 (el) Αναστολεις κρυσταλλικης βρωμο-περιοχης
CY1124412T1 (el) Aνti-dkk-1 αντισωματα
CY1116904T1 (el) Εμβολιο
CY1116571T1 (el) Ενωσεις φωσφορικου αμινοαλκυλο γλυκοζαμinιδιου και χρηση αυτων
CY1116075T1 (el) Νεες συνθεσεις λιποσωματων
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CY1122168T1 (el) Φαρμακοτεχνικες μορφες παραγωγων δεσιταβινης
CY1124950T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων, οπως του καρκινου του πνευμονα συμπεριλαμβανομενου του μμκπ
CY1111903T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
BRPI0923341B8 (pt) oligonucleotideo imunoestimulador, vacina compreendendo o mesmo e seu uso
CY1121326T1 (el) Υποκατεστημενη 2,4 διαμινο-κινολινη ως νεοι αντικαρκινικοι παραγοντες